Press release
Cholestatic Pruritus Market Expected to Experience Major Growth by 2032, According to DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma
DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.To Know in detail about the Cholestatic Pruritus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cholestatic Pruritus Market Forecast
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Cholestatic Pruritus Market Report:
• The Cholestatic Pruritus market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, Mirum Pharmaceuticals is actively enrolling participants in a Phase 3 clinical trial evaluating maralixibat for treatment-resistant pruritus associated with rare cholestatic conditions. Known as the EXPAND trial (NCT06553768), it aims to recruit up to 90 individuals aged six months and older across multiple sites in the U.S., South America, Europe, and the Middle East. Recruitment is currently underway at locations in Los Angeles, New Orleans, and New York, with enrollment expected to conclude in 2026, as detailed in a recent Mirum press release outlining financial and corporate updates.
• In November 2024, Ipsen (Euronext: IPN; ADR: IPSEY) presented data at the American Association for the Study of Liver Diseases (AASLD) evaluating the long-term efficacy and safety of Bylvay® in patients from two Phase III open-label extension studies. The late-breaking abstract (#5045) focused on the PEDFIC 2 study in Progressive Familial Intrahepatic Cholestasis (PFIC), while the oral presentation ASSERT-EXT (#50) examined its effects in Alagille syndrome (ALGS). Findings revealed sustained efficacy, along with improvements in height, weight, and sleep, for patients treated with Bylvay for at least 72 weeks in both rare cholestatic conditions.
• In November 2024, GSK reported positive topline results from its ongoing global Phase III GLISTEN trial, which is assessing linerixibat for treating cholestatic pruritus (persistent itching) in adults. Cholestatic pruritus is a frequent symptom of primary biliary cholangitis (PBC), a rare autoimmune liver disease. The study aims to evaluate the safety and effectiveness of linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in managing pruritus in PBC patients.
• According to research conducted by Yoshikawa et al. in 2021, pruritus prevalence is documented at 70% among individuals with primary biliary cholangitis (PBC). Additionally, pruritus has been observed in 8% of patients with chronic hepatitis B and in approximately 2.5-20% of those with chronic hepatitis C.
• Pruritus is commonly linked to cholestatic liver conditions such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Review articles suggest an occurrence of pruritus in approximately 20-70% of individuals with PBC and in 38% of those affected by PSC.
• Key Cholestatic Pruritus Companies: Escient Pharmaceuticals, GlaxoSmithKline, Mirum Pharmaceuticals, Albireo, Regeneron Pharmaceuticals, Avior Bio, and others
• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others
• The Cholestatic Pruritus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cholestatic Pruritus pipeline products will significantly revolutionize the Cholestatic Pruritus market dynamics.
Cholestatic Pruritus Overview
Cholestatic pruritus, also known as cholestatic itch, is a distressing symptom characterized by intense itching that occurs in individuals with cholestatic liver diseases. Cholestatic liver diseases are conditions where the flow of bile from the liver to the small intestine is impaired, leading to the accumulation of bile acids and other substances in the bloodstream.
Get a Free sample for the Cholestatic Pruritus Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Cholestatic Pruritus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cholestatic Pruritus Epidemiology Segmentation:
The Cholestatic Pruritus market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Cholestatic Pruritus
• Prevalent Cases of Cholestatic Pruritus by severity
• Gender-specific Prevalence of Cholestatic Pruritus
• Diagnosed Cases of Episodic and Chronic Cholestatic Pruritus
Download the report to understand which factors are driving Cholestatic Pruritus epidemiology trends @ Cholestatic Pruritus Epidemiology Forecast
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched during the study period. The analysis covers Cholestatic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cholestatic Pruritus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Cholestatic Pruritus Therapies and Key Companies
• EP547: Escient Pharmaceuticals
• Linerixibat: GlaxoSmithKline
• LUM001: Mirum Pharmaceuticals
• A4250: Albireo
• Dupilumab: Regeneron Pharmaceuticals
• AV104: Avior Bio
Discover more about therapies set to grab major Cholestatic Pruritus market share @ Cholestatic Pruritus Treatment Landscape
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Cholestatic Pruritus Market Strengths
• Increasing prevalence of Cholestatic Pruritus in the 7MM
• Complex underlying mechanisms have been identified and various therapeutic options developed.
Cholestatic Pruritus Market Opportunities
• Current treatments for cholestatic pruritus are inadequate, and additional, more effective therapeutic options are required.
Scope of the Cholestatic Pruritus Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cholestatic Pruritus Companies: , and others
• Key Cholestatic Pruritus Therapies: EP547, Linerixibat, LUM001, A4250, Dupilumab, AV104, and others
• Cholestatic Pruritus Therapeutic Assessment: Cholestatic Pruritus current marketed and Cholestatic Pruritus emerging therapies
• Cholestatic Pruritus Market Dynamics: Cholestatic Pruritus market drivers and Cholestatic Pruritus market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cholestatic Pruritus Unmet Needs, KOL's views, Analyst's views, Cholestatic Pruritus Market Access and Reimbursement
To know more about Cholestatic Pruritus companies working in the treatment market, visit @ Cholestatic Pruritus Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Cholestatic Pruritus Market Report Introduction
2. Executive Summary for Cholestatic Pruritus
3. SWOT analysis of Cholestatic Pruritus
4. Cholestatic Pruritus Patient Share (%) Overview at a Glance
5. Cholestatic Pruritus Market Overview at a Glance
6. Cholestatic Pruritus Disease Background and Overview
7. Cholestatic Pruritus Epidemiology and Patient Population
8. Country-Specific Patient Population of Cholestatic Pruritus
9. Cholestatic Pruritus Current Treatment and Medical Practices
10. Cholestatic Pruritus Unmet Needs
11. Cholestatic Pruritus Emerging Therapies
12. Cholestatic Pruritus Market Outlook
13. Country-Wise Cholestatic Pruritus Market Analysis (2019-2032)
14. Cholestatic Pruritus Market Access and Reimbursement of Therapies
15. Cholestatic Pruritus Market Drivers
16. Cholestatic Pruritus Market Barriers
17. Cholestatic Pruritus Appendix
18. Cholestatic Pruritus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Cholestatic Pruritus Pipeline https://www.delveinsight.com/report-store/cholestatic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Cholestatic Pruritus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cholestatic Pruritus market. A detailed picture of the Cholestatic Pruritus pipeline landscape is provided, which includes the disease overview and Cholestatic Pruritus treatment guidelines.
Cholestatic Pruritus Epidemiology https://www.delveinsight.com/report-store/cholestatic-pruritus-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cholestatic Pruritus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholestatic Pruritus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cholestatic Pruritus Market Expected to Experience Major Growth by 2032, According to DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma here
News-ID: 3888806 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cholestatic
Cholestatic Pruritus Market is expected to reach USD 3.4 billion by 2034
Cholestatic pruritus is one of the most debilitating complications of chronic liver diseases, particularly cholestasis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC). The persistent itching severely impairs patients' quality of life and remains a complex therapeutic challenge for healthcare providers worldwide. As awareness of liver disorders increases and pharmaceutical pipelines expand, the global cholestatic pruritus market is entering a transformative growth phase.
Download Full PDF Sample Copy of Market…
Global Cholestatic Pruritus Market Analysis 2025-2030: Growth Drivers, Challenge …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cholestatic Pruritus Market Size Expected to Be by 2034?
The market for cholestatic pruritus has experienced significant growth in the past few years. Projected to expand from $19.20 billion in 2024 to $20.28 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 5.6%. Factors contributing to…
Cholestatic Pruritus Market Size in 7MM is expected to grow at a decent CAGR by …
DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Cholestatic Pruritus Market Share @ Cholestatic Pruritus Market Outlook- https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Cholestatic Pruritus Market Report
• In March…
Cholestatic Pruritus Treatment Market Size in 7MM is expected to grow at a decen …
DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032" Report delivers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the Cholestatic Pruritus Market Share @ Cholestatic Pruritus Market Outlook- https://www.delveinsight.com/sample-request/cholestatic-pruritus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Cholestatic Pruritus Market Report
• In April…
Cholestatic Pruritus Market to Observe Impressive Growth During the Forecast Per …
The Cholestatic Pruritus Market Forecast report offers an in-depth understanding of the Cholestatic Pruritus, historical and forecasted epidemiology as well as the Cholestatic Pruritus market trends in the 7MM.
Cholestatic Pruritus Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Escient Pharma, GlaxoSmithKline, Mirum Pharma, Albireo, Regeneron Pharma
DelveInsight's "Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Cholestatic Pruritus, historical and…
Ursodeoxycholic Acid Market End-Products Increased the Demand by The Rise in Cas …
Demand Analysis of Ursodeoxycholic Acid Market Overview:
Ursodeoxycholic Acid Market is predicted to grow at a moderate CAGR of 11% during the forecast period covering 2022 to 2029. Ursodeoxycholic Acid Market share is estimated to reach a value of nearly US$ 1105 million by 2029.
The "Ursodeoxycholic Acid Market" think about 2022, the industry landscape is secured from driving factors to upstream markets and the by and large state of the market.…